28 August 2024
RUA Life Sciences plc
("RUA" the "Company" or the "Group")
Result of AGM
RUA Life Sciences plc (AIM:RUA.L), the holding company of a group of medical device businesses focussed on the exploitation of the world's leading long-term implantable biostable polymer (Elast-Eon ™), announces that all resolutions put forward to its Annual General Meeting held yesterday were duly passed and the votes cast were as follows:
|
Res No. |
Votes For |
% |
Votes Against |
% |
Votes Withheld |
|
01 |
6,051,300 |
99.37% |
38,570 |
0.63% |
0 |
|
02 |
6,050,279 |
99.36% |
38,783 |
0.64% |
808 |
|
03 |
6,051,300 |
99.37% |
38,570 |
0.63% |
0 |
|
04 |
6,045,927 |
99.28% |
43,943 |
0.72% |
0 |
|
05 |
6,045,698 |
99.27% |
44,172 |
0.73% |
0 |
|
06 |
5,941,757 |
97.57% |
148,113 |
2.43% |
0 |
|
07 |
5,941,757 |
97.57% |
148,113 |
2.43% |
0 |
The full text of each of the resolutions is set out in the notice of Annual General Meeting, copies of which are available on the Company's website (www.rualifesciences.com).
For further information contact:
|
RUA Life Sciences |
Tel: +44 (0)1294 317073 |
|
Bill Brown, CEO |
|
|
Lachlan Smith, CFO |
|
|
|
|
|
Cavendish Capital Markets Limited |
|
|
(Nominated Adviser and Broker) |
Tel: +44 (0)20 7220 0500 |
|
Giles Balleny/Dan Hodkinson (Corporate Finance) |
|
|
Charlie Combe (Broking) |
|
|
Michael Johnson (Sales) |
|
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
